NCT03413982 Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers
| NCT ID | NCT03413982 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Kansas Medical Center |
| Condition | Bladder Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2017-11-02 |
| Primary Completion | 2035-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2017-11-02 with a primary completion date of 2035-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments. The registry will be used by researchers to learn more about long term outcome of patients with bladder cancer, how bladder cancer tissues are related to tumor development, recurrence and survival.
Eligibility Criteria
Inclusion Criteria: * Patients who present to clinic with presumed bladder cancer or have a diagnosis of bladder cancer are eligible to participate * Patients can participate in any additional research studies during the patients' participation within this protocol. Exclusion Criteria: * Patients who do not have presumed bladder cancer will not be eligible
Contact & Investigator
John Taylor, MD
PRINCIPAL INVESTIGATOR
University of Kansas Medical Center
Frequently Asked Questions
Who can join the NCT03413982 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bladder Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03413982 currently recruiting?
Yes, NCT03413982 is actively recruiting participants. Contact the research team at jledesma2@kumc.edu for enrollment information.
Where is the NCT03413982 trial being conducted?
This trial is being conducted at Kansas City, United States.
Who is sponsoring the NCT03413982 clinical trial?
NCT03413982 is sponsored by University of Kansas Medical Center. The principal investigator is John Taylor, MD at University of Kansas Medical Center. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.